Comparative morphology of statocysts in the Plathelminthes and the Xenoturbellida

U. Ehlers

DOI: https://doi.org/10.1007/BF00027611

IF: 2.822

1991-12-01

Hydrobiologia

Abstract:

What problem does this paper attempt to address?

Effects of COVID-19 on Arrhythmia

Yujia Zhan,Honghua Yue,Weitao Liang,Zhong Wu

DOI: https://doi.org/10.3390/jcdd9090292

2022-09-02

Journal of Cardiovascular Development and Disease

Abstract:The World Health Organization announced that COVID-19, with SARS-CoV-2 as its pathogen, had become a pandemic on 11 March 2020. Today, the global epidemic situation is still serious. With the development of research, cardiovascular injury in patients with COVID-19, such as arrhythmia, myocardial injury, and heart failure, is the second major symptom in addition to respiratory symptoms, and cardiovascular injury is related to the prognosis and mortality of patients. The incidence of arrhythmia in COVID-19 patients ranges from 10% to 20%. The potential mechanisms include viral infection-induced angiotensin-converting enzyme 2 expression change, myocarditis, cytokine storm, cardiac injury, electrophysiological effects, hypoxemia, myocardial strain, electrolyte abnormalities, intravascular volume imbalance, drug toxicities and interactions, and stress response caused by virus infection. COVID-19 complicated with arrhythmia needs to be accounted for and integrated in management. This article reviews the incidence, potential mechanisms, and related management measures of arrhythmia in COVID-19 patients.

cardiac & cardiovascular systems
2023 Chinese Expert Consensus on the Impact of COVID-19 on the Management of Cardiovascular Diseases

Feng Bai,Jun Pu,Wenliang Che,Jiyan Chen,Mao Chen,Wei Chen,Xiaoping Chen,Yundai Chen,Xianwu Cheng,Xiang Cheng,Hongliang Cong,Cuilian Dai,Dali Fan,Guosheng Fu,Lei Gao,Chuanyu Gao,Wei Gao,Junbo Ge,Ben He,Tao Hu,Congxin Huang,Jing Huang,Yong Huo,Shaobin Jia,Jun Jiang,Zhicheng Jing,Xiangqing Kong,Lang Li,Yan Li,Yigang Li,Zhijuan Li,Chun Liang,Xianhe Lin,Xianxia Liu,Xuebo Liu,Chengzhi Lu,Genshan Ma,Yitong Ma,Wei Mao,Xia Mei,Zhongping Ning,Jiafu Ou,Shaderdin Slaj,Chengxing Shen,Haiming Shi,Hong Shi,Bei Shi,Xi Su,Ningling Sun,Qizhu Tang,Fang Wang,Changqian Wang,Jin Wang,Yanqing Wu,Yongjian Wu,Yunlong Xia,Dingcheng Xiang,Pingxi Xiao,Ping Xie,Dingding Xiong,Yawei Xu,Jiefu Yang,Lixia Yang,Zaixin Yu,Zuyi Yuan,Haitao Yuan,Guogang Zhang,Heng Zhang,Jian Zhang,Li Zhang,Ruiyan Zhang,Shuning Zhang,Shuyang Zhang,Zheng Zhang,Guoan Zhao,Xianxian Zhao,Jingang Zheng,Haoyi Zheng,Daxin Zhou,Shenghua Zhou,Yujie Zhou

DOI: https://doi.org/10.1097/cp9.0000000000000043

2023-01-01

Cardiology Plus

Abstract:The primary site of infection in COVID-19 exhibit is the respiratory system, but multiple organ systems could be affected. The virus could directly invade cardiomyocytes. Alternatively, cytokine storm could lead to myocardial injury. More importantly, the management of existing cardiovascular diseases must be re-examined in COVID-19 due to, for example, interaction between antiviral agents and with a wide variety of pharmacological agents. The Branch of Cardiovascular Physicians of Chinese Medical Doctor Association organized a panel of experts in cardiovascular and related fields to discuss this important issue, and formulated the "2023 Chinese Expert Consensus on the Impact of COVID-19 on the Management of Cardiovascular Diseases." The Consensus was drafted on the basis of systematic review of existing evidence and diagnosis and treatment experience, and covers three major aspects: myocardial injury caused by COVID-10 and COVID-19 vaccine, the impact of COVID-19 on patients with cardiovascular disease, and the impact of COVID-19 on the cardiovascular system of healthy people, and rehabilitation guidance recommendations. The Consensus involves 11 core clinical issues, including incidence, pathogenesis, clinical manifestations, treatment strategies, prognosis, and rehabilitation. It is our hope that this Consensus will provide a practical guidance to cardiologists in the management of cardiovascular diseases in the new era of COVID-19 pandemic.
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Tomasz J Guzik,Saidi A Mohiddin,Anthony Dimarco,Vimal Patel,Kostas Savvatis,Federica M Marelli-Berg,Meena S Madhur,Maciej Tomaszewski,Pasquale Maffia,Fulvio D’Acquisto,Stuart A Nicklin,Ali J Marian,Ryszard Nosalski,Eleanor C Murray,Bartlomiej Guzik,Colin Berry,Rhian M Touyz,Reinhold Kreutz,Dao Wen Wang,David Bhella,Orlando Sagliocco,Filippo Crea,Emma C Thomson,Iain B McInnes

DOI: https://doi.org/10.1093/cvr/cvaa106

IF: 13.081

2020-04-30

Cardiovascular Research

Abstract:Abstract The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades. We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies. While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system. Risk of severe infection and mortality increase with advancing age and male sex. Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer. The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC). Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) —a homologue of ACE—to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes. This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI). While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis. Hence, patients should not discontinue their use. Moreover, renin–angiotensin–aldosterone system (RAAS) inhibitors might be beneficial in COVID-19. Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19. Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications. Preventive measures (social distancing and social isolation) also increase cardiovascular risk. Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.

cardiac & cardiovascular systems
Covid-19 and the cardiovascular system: a comprehensive review

Rafael Bellotti Azevedo,Bruna Gopp Botelho,João Victor Gonçalves de Hollanda,Leonardo Villa Leão Ferreira,Letícia Zarur Junqueira de Andrade,Stephanie Si Min Lilienwald Oei,Tomás de Souza Mello,Elizabeth Silaid Muxfeldt

DOI: https://doi.org/10.1038/s41371-020-0387-4

2020-07-27

Journal of Human Hypertension

Abstract:Cardiac injury in patients infected with the novel Coronavirus (COVID-19) seems to be associated with higher morbimortality. We provide a broad review of the clinical evolution of COVID-19, emphasizing its impact and implications on the cardiovascular system. The pathophysiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by overproduction of inflammatory cytokines (IL-6 and TNF-α) leading to systemic inflammation and multiple organ dysfunction syndrome, acutely affecting the cardiovascular system. Hypertension (56.6%) and diabetes (33.8%) are the most prevalent comorbidities among individuals with COVID-19, who require hospitalization. Furthermore, cardiac injury, defined as elevated us-troponin I, significantly relates to inflammation biomarkers (IL-6 and C-reactive protein (CRP), hyperferritinemia, and leukocytosis), portraying an important correlation between myocardial injury and inflammatory hyperactivity triggered by viral infection. Increased risk for myocardial infarction, fulminant myocarditis rapidly evolving with depressed systolic left ventricle function, arrhythmias, venous thromboembolism, and cardiomyopathies mimicking STEMI presentations are the most prevalent cardiovascular complications described in patients with COVID-19. Moreover, SARS-CoV-2 tropism and interaction with the RAAS system, through ACE2 receptor, possibly enhances inflammation response and cardiac aggression, leading to imperative concerns about the use of ACEi and ARBs in infected patients. Cardiovascular implications result in a worse prognosis in patients with COVID-19, emphasizing the importance of precocious detection and implementation of optimal therapeutic strategies.

peripheral vascular disease
Cardiac injuries in coronavirus disease 2019 (COVID-19)

Chen Chen,Huihui Li,Weijian Hang,Dao Wen Wang

DOI: https://doi.org/10.1016/j.yjmcc.2020.06.002

IF: 5.763

2020-08-01

Journal of Molecular and Cellular Cardiology

Abstract:As the coronavirus disease 2019 (COVID-19) epidemic worsens, this global pandemic is impacting more than 200 countries/regions and more than 4,500,000 confirmed cases worldwide. COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which might attack not only the respiratory system, but also the other important organs, including the heart. It was reported that COVID-19 patients with a past history of cardiovascular diseases would have a higher mortality. Meanwhile, elevated troponin levels were frequently observed in COVID-19 cases. Besides the comprehensive treatments for COVID-19, as a cardiologist, we should also remain vigilant about the cardiac injuries, especially those with severe emergent cardiovascular symptoms.

cardiac & cardiovascular systems,cell biology
Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019

Wenyi Peng,Hao Wu,Yan Tan,Mei Li,Dachun Yang,Shuang Li

DOI: https://doi.org/10.1016/j.lfs.2020.118496

IF: 6.78

2020-12-01

Life Sciences

Abstract:The infection epidemic event of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was formally declared a pandemic by World Health Organization on March 11th, 2020. Corona Virus Disease 2019 (COVID-19) is caused by SARS-CoV-2, a new type of coronavirus, which has high contagion and mainly causes respiratory symptoms. With the increase in confirmed cases, however, the infection symptoms turn to be diverse with secondary or first clinical symptoms relating to damage of the cardiovascular system and changes of myocardial enzyme spectrum, cardiac troponin I, electrocardiogram, cardiac function. The occurrence of extra-pulmonary manifestations, including immediately and long-term damage, means that the overall health burden caused by SARS-CoV-2 infection may be under-estimated because COVID-19 patients developed cardiovascular system injury are more likely to become serious. The factors such as directly pathogen-mediated damage to cardiomyocytes, down-regulated angiotensin-converting enzyme 2 (ACE2) expression, excessive inflammatory response, hypoxia and adverse drug reaction, are closely related to the occurrence and development of the course of COVID-19. In combination with recently published medical data of patients having SARS-CoV-2 infection and the latest studies, the manifestations of damage to cardiovascular system by COVID-19, possible pathogenic mechanisms and advances of the treatment are proposed in this article.

pharmacology & pharmacy,medicine, research & experimental
[The heart remembers...and if we remember that, unnecessary examinations can be avoided].

L. Wecke,L. Bergfeldt

Abstract:
COVID-19 and cardiovascular complications: updates of emergency medicine

Jianli Zhao,Yaoli Xie,Zhijun Meng,Caihong Liu,Yalin Wu,Fujie Zhao,Xinliang Ma,Theodore A Christopher,Bernard J Lopez,Yajing Wang

DOI: https://doi.org/10.1097/ec9.0000000000000095

Abstract:Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV-2 variants, has become a global pandemic resulting in significant morbidity and mortality. Severe cases of COVID-19 are characterized by hypoxemia, hyper-inflammation, cytokine storm in lung. Clinical studies have reported an association between COVID-19 and cardiovascular disease (CVD). Patients with CVD tend to develop severe symptoms and mortality if contracted COVID-19 with further elevations of cardiac injury biomarkers. Furthermore, COVID-19 itself can induce and promoted CVD development, including myocarditis, arrhythmia, acute coronary syndrome, cardiogenic shock, and venous thromboembolism. Although the direct etiology of SARS-CoV-2 induced cardiac injury remains unknown and under-investigated, it is suspected that it is related to myocarditis, cytokine-mediated injury, microvascular injury, and stress-related cardiomyopathy. Despite vaccinations having provided the most effective approach to reducing mortality overall, an adapted treatment paradigm and regular monitoring of cardiac injury biomarkers is critical for improving outcomes in vulnerable populations at risk for severe COVID-19. In this review, we focus on the latest progress in clinic and research on the cardiovascular complications of COVID-19 and provide a perspective of treating cardiac complications deriving from COVID-19 in Emergency Medicine.
Prevalence, Clinical Characteristics and Outcomes of COVID-19 Combined with Cardiac Injury

Jian He,Bicheng Zhang,Quan Zhou,Wenjing Wang,Jing Xu,Tingting Liu,Haijun Zhang,Zhiyong Wu,Dong Li,Qing Zhou,Jie Yan,Cuizhen Zhang,Robert G. Weiss,Guanshu Liu,Zhongzhao Teng,Arlene Sirajuddin,Haiyan Qian,Shihua Zhao,Andrew E. Arai,Qizhu Tang,Minjie Lu,Xiaoyang Zhou

DOI: https://doi.org/10.2139/ssrn.3576807

2020-01-01

Abstract:Background: Since December 2019, Coronavirus disease 2019 (COVID-19) has emerged as an international pandemic. COVID-19 patients with cardiac injury might need special attention. However, understanding on this aspect remains unclear.Methods: This retrospective, single-center study included 304 COVID-19 cases hospitalized from January 11 to March 25, 2020. Confirmed by real-time RT-PCR, cases were analyzed for clinical characteristics and complications, specifically with cardiac injury, determined by the serum biomarker hypersensitive troponin I. The primary endpoint was COVID-19 associated mortality.Findings: Of the 304 patients, 96 (31∙6%) patients had cardiac injury and 208 (68∙4%) patients presented without cardiac injury. The median age was 65 (interquartile range, IQR, 54-74) years, and 160 (52∙6%) of COVID-19 patients were men. COVID-19 patients with cardiac injury had more comorbidities (76[79∙2%] vs 122[58∙7%], p<0∙001), and they had lower lymphocyte counts (median[IQR], 0∙6[0∙4-1∙0] vs 1∙0[0∙7-1∙3]/L, P<0∙001), while higher C-reactive protein levels (median[IQR], 84∙9[53∙7-173∙8] vs 28∙5[5∙7-82∙2]mg/L, p<0∙001) and procalcitonin levels (median[IQR], 0∙29[0∙10-1∙09] vs 0∙06[0∙04-0∙14]ng/mL, p<0∙001) and more frequent use of noninvasive ventilation (35[36∙5%] vs 27[13∙0%]), invasive mechanical ventilation (20[20∙8%] vs 11[5∙3%]) and antibiotic treatment (65[67∙7%] vs 53[25∙5%]) compared with patients without cardiac injury. The mortality rate in patients with cardiac injury was much higher than those without (63∙5%, 61/96 vs 13∙0%, 27/208, p<0∙001). The Cox regression showed cardiac injury was the strongest independent predictor to mortality from symptom onset in COVID-19 patients (hazard ratio[HR], 3∙37[95% CI, 1∙90-5∙67], p<0∙001).Interpretation: Cardiac injury is associated with more severe presentation, complex comorbidities and is the strongest independent predictor to mortality in hospitalized patients with COVID-19.Funding Statement: This study received the following funding: Construction Research Project of Key Laboratory (Cultivation) of Chinese Academy of Medical Sciences(No. 2019PT310025); National Natural Science Foundation of China (No. 81971588 and 81771811); Capital Clinically Characteristic Applied Research Fund (No. Z191100006619021); National Foreign Expert Talent Project(No. G20190001630); Education Reform Project of Peking Union Medical College (No. 10023201900204); Clinical and Translational Fund of Chinese Academy of Medical Sciences (No. 2019XK320063); National Natural Science Foundation of China (No. 81970331). Declaration of Interests: The authors declare no competing interests.Ethics Approval Statement: Local ethic approval (Ref: WDRY2020-K094).
Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment

Jinwen Luo,Xiao Zhu,Jie Jian,Xu Chen,Kai Yin

DOI: https://doi.org/10.1093/abbs/gmaa176

IF: 3.7

2021-01-11

Acta Biochimica et Biophysica Sinica

Abstract:Abstract The coronavirus disease-2019 (COVID-19) caused by the novel coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has rapidly developed into a global pneumonia pandemic. Cardiovascular disease is the major comorbidity of COVID-19 patients and is closely related to the severity of COVID-19. SARS-CoV-2 infection can directly or indirectly cause a series of cardiac complications, including acute myocardial injury and myocarditis, heart failure and cardiac arrest, arrhythmia, acute myocardial infarction, cardiogenic shock, Takotsubo cardiomyopathy, and coagulation abnormalities. Intensive research on the SARS-CoV-2-associated cardiovascular complications is urgently needed to elucidate its exact mechanism and to identify potential drug targets, which will help to formulate effective prevention and treatment strategies. Hence, this review will summarize recent progress regarding the effects of COVID-19 on the cardiovascular system and describe the underlying mechanism of cardiovascular injury caused by SARS-CoV-2.

biochemistry & molecular biology,biophysics
COVID-19 Associated Cardiovascular Disease—Risks, Prevention and Management: Heart at Risk Due to COVID-19

Andrew Kemerley,Abhishek Gupta,Mahesh Thirunavukkarasu,Monica Maloney,Sean Burgwardt,Nilanjana Maulik

DOI: https://doi.org/10.3390/cimb46030124

2024-02-29

Current Issues in Molecular Biology

Abstract:The SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) virus and the resulting COVID-19 pandemic have had devastating and lasting impact on the global population. Although the main target of the disease is the respiratory tract, clinical outcomes, and research have also shown significant effects of infection on other organ systems. Of interest in this review is the effect of the virus on the cardiovascular system. Complications, including hyperinflammatory syndrome, myocarditis, and cardiac failure, have been documented in the context of COVID-19 infection. These complications ultimately contribute to worse patient outcomes, especially in patients with pre-existing conditions such as hypertension, diabetes, or cardiovascular disease (CVD). Importantly and interestingly, reports have demonstrated that COVID-19 also causes myocardial injury in adults without pre-existing conditions and contributes to systemic complications in pediatric populations, such as the development of multisystem inflammatory syndrome in children (MIS-C). Although there is still a debate over the exact mechanisms by which such complications arise, understanding the potential paths by which the virus can influence the cardiovascular system to create an inflammatory environment may clarify how SARS-CoV-2 interacts with human physiology. In addition to describing the mechanisms of disease propagation and patient presentation, this review discusses the diagnostic findings and treatment strategies and the evolution of management for patients presenting with cardiovascular complications, focusing on disease treatment and prevention.

biochemistry & molecular biology
The effects of water-soluble solutes on the phase transitions of phospholipids.

J. Sturtevant

DOI: https://doi.org/10.1073/PNAS.81.5.1398

1984-03-01

Abstract:A previous treatment [Sturtevant, J.M. (1982) Proc. Natl. Acad. Sci. USA 79, 3963-3967], based on ideal solution theory, of the influence of small molecules on the main phase transitions of phospholipid bilayers is extended to include the effect of water solubility of the added solute. This effect is manifested primarily in a sharpening of the phase transition, resulting from a buffering by the aqueous phase of the concentration of the solute in the lipid phases.
Cardiac sequelae of novel coronavirus disease 2019 (COVID-19): a clinical case series

Zachary D Demertzis,Carina Dagher,Kelly M Malette,Raef A Fadel,Patrick B Bradley,Indira Brar,Bobak T Rabbani,Geehan Suleyman

DOI: https://doi.org/10.1093/ehjcr/ytaa179

2020-06-13

Abstract:Background: COVID-19 caused by severe acute respiratory syndrome coronavirus 2 most commonly manifests with fever and respiratory illness. The cardiovascular manifestations have become more prevalent but can potentially go unrecognized. We look to describe cardiac manifestations in three patients with COVID-19 using cardiac enzymes, electrocardiograms, and echocardiography. Case summaries: The first patient, a 67-year-old Caucasian female with non-ischaemic dilated cardiomyopathy, presented with dyspnoea on exertion and orthopnoea 1 week after testing positive for COVID-19. Echocardiogram revealed large pericardial effusion with findings consistent with tamponade. A pericardial drain was placed, and fluid studies were consistent with viral pericarditis, treated with colchicine, hydroxychloroquine, and methylprednisolone. Follow-up echocardiograms showed apical hypokinesis, that later resolved, consistent with Takotsubo syndrome. The second patient, a 46-year-old African American male with obesity and type 2 diabetes mellitus presented with fevers, cough, and dyspnoea due to COVID-19. Clinical course was complicated with pulseless electrical activity arrest; he was found to have D-dimer and troponin elevation, and inferior wall ST elevation on ECG concerning for STEMI due to microemboli. The patient succumbed to the illness. The third patient, a 76-year-old African American female with hypertension, presented with diarrhoea, fever, and myalgia, and was found to be COVID-19 positive. Clinical course was complicated, with acute troponin elevation, decreased cardiac index, and severe hypokinesis of the basilar wall suggestive of reverse Takotsubo syndrome. The cardiac index improved after pronation and non-STEMI therapy; however, the patient expired due to worsening respiratory status. Discussion: These case reports demonstrate cardiovascular manifestations of COVID-19 that required monitoring and urgent intervention.
Cardiac Injury and Clinical Course of Patients With Coronavirus Disease 2019

Yushi Wang,Yang Zheng,Qian Tong,Lihui Wang,Guorui Lv,Ziwei Xi,Wei Liu

DOI: https://doi.org/10.3389/fcvm.2020.00147

IF: 3.6

2020-08-25

Frontiers in Cardiovascular Medicine

Abstract:Background: Cardiac injury is recognized as one of the most common critical complications during exacerbation of coronavirus disease 2019 (COVID-19). This study aimed to investigate the effect of cardiac injury on the clinical course of COVID-19 and to examine its potential mechanism and treatments.Methods and Results: A total of 222 hospitalized patients with COVID-19 from Wuhan were selected for the study during February 10 to March 28, 2020. Demographic, laboratory, and clinical data on admission and during hospitalization were compared between patients with COVID-19 with or without cardiac injury. On admission, cardiac injury (n = 29) was associated with advanced age, more underlying coronary artery disease, and a lower PaO2. Troponin levels were correlated with inflammatory markers (C-reactive protein: r = 0.348, P < 0.001; interleukin 6: r = 0.558, P < 0.001) and D-dimer levels (r = 0.598, P < 0.001). During hospitalization, another six patients suffered from cardiac injury and cardiac injury (n = 35), resulting in higher rates of ventilation (invasive: 51.4 vs. 1.6%, P < 0.001; non-invasive: 31.4 vs. 1.1%, P < 0.001) and mortality (54.3 vs. 1.1%, P < 0.001). Cardiac injury on admission was a predictive factor for mortality (adjusted hazard ratio = 4.73, 95% confidence interval = 1.35–16.63, P = 0.015). Receiver operating characteristic curve analysis showed that, on admission, a troponin level of 36.35 pg/mL was predictive for mortality with a sensitivity of 73.7% and a specificity of 92.1%.Conclusions: Cardiac injury complicates the disease course and increases the mortality rate of COVID-19. Troponin levels should be checked at admission and during hospitalization for triage, better monitoring, and managing those with COVID-19, especially in the most severe patients.Condensed Cardiac injury is not uncommon in COVID-19. In a cohort of 222 patients with COVID-19, cardiac injury was found in 29 patients on admission and in another 6 patients during hospitalization. The admission level of troponin was well-correlated with inflammatory factors and D-dimer levels and strongly predicted mortality. Cardiac injury is a manifestation secondary to hypoxia and systemic infection, but which nevertheless further complicates the disease course and increases the mortality rate. Troponin levels should be checked at admission and during hospitalization for triage, better monitoring, and managing those with COVID-19, especially in the most severe patients.

cardiac & cardiovascular systems
Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)

Edina Cenko,Lina Badimon,Raffaele Bugiardini,Marc J Claeys,Giuseppe De Luca,Cor de Wit,Geneviève Derumeaux,Maria Dorobantu,Dirk J Duncker,Etto C Eringa,Diana A Gorog,Christian Hassager,Frank R Heinzel,Kurt Huber,Olivia Manfrini,Davor Milicic,Evangelos Oikonomou,Teresa Padro,Danijela Trifunovic-Zamaklar,Zorana Vasiljevic-Pokrajcic,Marija Vavlukis,Gemma Vilahur,Dimitris Tousoulis

DOI: https://doi.org/10.1093/cvr/cvab298

IF: 13.081

2021-09-16

Cardiovascular Research

Abstract:Abstract The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19). Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or indirectly related to the intense systemic inflammatory and immune responses are characteristic features of severe COVID-19. Pre-existing cardiovascular disease and viral load are linked to myocardial injury and worse outcomes. The vascular response to cytokine production and the interaction between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and angiotensin-converting enzyme 2 receptor may lead to a significant reduction in cardiac contractility and subsequent myocardial dysfunction. In addition, a considerable proportion of patients who have been infected with SARS-CoV-2 do not fully recover and continue to experience a large number of symptoms and post-acute complications in the absence of a detectable viral infection. This conditions often referred to as ‘post-acute COVID-19’ may have multiple causes. Viral reservoirs or lingering fragments of viral RNA or proteins contribute to the condition. Systemic inflammatory response to COVID-19 has the potential to increase myocardial fibrosis which in turn may impair cardiac remodelling. Here, we summarize the current knowledge of cardiovascular injury and post-acute sequelae of COVID-19. As the pandemic continues and new variants emerge, we can advance our knowledge of the underlying mechanisms only by integrating our understanding of the pathophysiology with the corresponding clinical findings. Identification of new biomarkers of cardiovascular complications, and development of effective treatments for COVID-19 infection are of crucial importance.

cardiac & cardiovascular systems
Coronavirus disease 2019 and cardiovascular complications: focused clinical review

Sahrai Saeed,Marijana Tadic,Terje H. Larsen,Guido Grassi,Giuseppe Mancia

DOI: https://doi.org/10.1097/hjh.0000000000002819

IF: 4.9

2021-02-26

Journal of Hypertension

Abstract:The coronavirus disease 2019 (COVID-19) may cause not only an acute respiratory distress syndrome (ARDS) but also multiple organ damage and failure requiring intensive care and leading to death. Male sex, advanced age, chronic lung disease, chronic kidney disease and cardiovascular disease, such as hypertension, diabetes and obesity have been identified as risk factors for the COVID-19 severity. Presumably, as these three cardiovascular risk factors are associated with a high prevalence of multiorgan damage. In the present focused clinical review, we will discuss the cardiovascular complications of COVID-19 including acute cardiovascular syndrome (acute cardiac injury/COVID cardiomyopathy, thromboembolic complications and arrhythmias) and post-COVID-19 sequelae. Preliminary data shows that the cause of acute cardiovascular syndrome may be multifactorial and involve direct viral invasion of the heart and vascular system, as well as through the immune and inflammation-mediated systemic cytokine storm. COVID-19 survivors may also show persistently elevated blood pressure and sinus tachycardia at rest. Furthermore, poor diabetic control, persistent renal damage and cerebral sequelae, such as persistent cognitive and neuropsychiatric alterations are also frequently reported. A particular attention should be paid towards cardiovascular protection in COVID-19 patients who develop acute cardiovascular syndromes during hospitalization, and/or permanent/semipermanent sequelae after recovery from COVID-19. These conditions may require careful clinical assessment, treatment and close follow-up to avoid short-term and long-term complications.

peripheral vascular disease
Clinical Characterization and Possible Pathological Mechanism of Acute Myocardial Injury in COVID-19

Siyi Li,Jinan Wang,Yan Yan,Zekun Zhang,Wei Gong,Shaoping Nie

DOI: https://doi.org/10.3389/fcvm.2022.862571

IF: 3.6

2022-03-21

Frontiers in Cardiovascular Medicine

Abstract:COVID-19 is a respiratory disease that can cause damage to multiple organs throughout the body. Cardiovascular complications related to COVID-19 mainly include acute myocardial injury, heart failure, acute coronary syndrome, arrhythmia, myocarditis. Among them, myocardial injury is the most common complication in COVID-19 hospitalized patients, and is associated with poor prognosis such as death and arrhythmias. There is a continuous relationship between myocardial injury and the severity of COVID-19. The incidence of myocardial injury is higher in critically ill patients and dead patients, and myocardial injury is more likely to occur in the elderly critically ill patients with comorbidities. Myocardial injury is usually accompanied by more electrocardiogram abnormalities, higher inflammation markers and more obvious echocardiographic abnormalities. According to reports, COVID-19 patients with a history of cardiovascular disease have a higher in-hospital mortality, especially in the elder patients. At present, the mechanism of myocardial injury in COVID-19 is still unclear. There may be direct injury of myocardial cells, systemic inflammatory response, hypoxia, prethrombotic and procoagulant state, myocardial interstitial fibrosis, interferon-mediated immune response and coronary artery plaque instability and other related factors, and angiotensin-converting enzyme-2 receptor may play a key role in the myocardial injury in COVID-19.

cardiac & cardiovascular systems
NEUROTIC INSTABILITY IN A DUTCH VILLAGE

R. Giel,C. Nobel

DOI: https://doi.org/10.1111/j.1600-0447.1971.tb03703.x

1971-12-01

Acta Psychiatrica Scandinavica

Abstract:
COVID-19 and the Heart: Lessons Learned and Future Research Directions

Tetz Cheng-Che Lee,Alaa Mabrouk Salem Omar,Jonathan N. Bella

DOI: https://doi.org/10.3390/cardiogenetics14010004

2024-03-19

Cardiogenetics

Abstract:It has become evident that acute COVID-19 infection can lead to cardiovascular complications. While the exact mechanisms by which COVID-19 affects the cardiovascular system have yet to be fully elucidated, several mechanisms have been proposed, including direct myocardial effects on the virus and systemic inflammation as an indirect result. The cardiovascular complications of COVID-19 have been characterized and described using noninvasive cardiac imaging. The impact of COVID-19 on the cardiovascular system extends beyond the acute phase of the infection and well beyond recovery or the convalescent period. However, the underlying mechanisms of post-viral long-COVID symptoms have yet to be elucidated. It is evident that COVID-19 has become endemic and is here to stay. Future studies are needed (1) to understand the long-term effects of the cardiovascular complications of COVID-19, future cardiovascular events and the impact of mutating variants on cardiovascular complications through data collection and analysis, (2) to identify the most important diagnostic criteria for prognosis of COVID-19 and to understand the disease mechanism through biomarkers and advanced cardiac imaging, including echocardiography and (3) to develop novel strategies to manage and treat these cardiovascular complications using the knowledge gained.
Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool

Sara Momtazmanesh,Parnian Shobeiri,Sara Hanaei,Hani Mahmoud-Elsayed,Bharat Dalvi,Elaheh Malakan Rad

DOI: https://doi.org/10.1186/s43044-020-00075-z

2020-07-13

The Egyptian Heart Journal

Abstract:Abstract Background Coronavirus disease 2019 (COVID-19) pandemic has drastically affected global health. Despite several studies, there is yet a dearth of data regarding the mechanisms of cardiac injury, clinical presentation, risk factors, and treatment of COVID-19-associated cardiovascular disease. This systematic review and meta-analysis is aimed at defining the clinical, electrocardiographic, and pathologic spectrum of cardiovascular disease (CVD), frequency of elevated cardiac and inflammatory biomarkers, and their frequency and relationship with severity of the disease and mortality in COVID-19 patients and to develop a triage risk stratification tool (TRST) that can serve as a guide for the timely recognition of the high-risk patients and mechanism-targeted therapy. We conducted an online search in databases of PubMed and Embase to identify relevant studies. Data selection was in concordance with PRISMA guidelines. Results were presented as pooled frequencies, odds ratio, standardized mean difference (SMD), and forest and funnel plots. Results We gathered a total of 54 studies and included 35 of them in our meta-analysis. Acute cardiac injury occurred in more than 25% of cases, mortality was 20 times higher, and admission to intensive care unit increased by 13.5 times. Hypertension was the most common pre-existing comorbidity with a frequency of 29.2%, followed by diabetes mellitus (13.5%). The deceased group of patients had higher cardiac and inflammatory biomarkers, with statistically significant SMD, compared with survivors. Pediatric patients were predominantly mildly affected. However, less frequently, the presentation was very similar to Kawasaki disease or Kawasaki shock syndrome. This latter presentation hass been called as multisystem inflammatory syndrome in children (MIS-C). Conclusions There is a wide spectrum of cardiac involvement in COVID-19 patients, and hence a Triage Risk Stratification Tool can serve as a guide for the timely recognition of the high-risk patients and mechanism-targeted therapy.

Comparative morphology of statocysts in the Plathelminthes and the Xenoturbellida

Effects of COVID-19 on Arrhythmia

2023 Chinese Expert Consensus on the Impact of COVID-19 on the Management of Cardiovascular Diseases

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Covid-19 and the cardiovascular system: a comprehensive review

Cardiac injuries in coronavirus disease 2019 (COVID-19)

Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019

[The heart remembers...and if we remember that, unnecessary examinations can be avoided].

COVID-19 and cardiovascular complications: updates of emergency medicine

Prevalence, Clinical Characteristics and Outcomes of COVID-19 Combined with Cardiac Injury

Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment

COVID-19 Associated Cardiovascular Disease—Risks, Prevention and Management: Heart at Risk Due to COVID-19

The effects of water-soluble solutes on the phase transitions of phospholipids.

Cardiac sequelae of novel coronavirus disease 2019 (COVID-19): a clinical case series

Cardiac Injury and Clinical Course of Patients With Coronavirus Disease 2019

Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)

Coronavirus disease 2019 and cardiovascular complications: focused clinical review

Clinical Characterization and Possible Pathological Mechanism of Acute Myocardial Injury in COVID-19

NEUROTIC INSTABILITY IN A DUTCH VILLAGE

COVID-19 and the Heart: Lessons Learned and Future Research Directions

Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool